33 / 39
Could we personalise 1
st
line treatment?
ALK
is an heterogeneous disease (>19 fusions)
Gridelli – CTR 2014 * Christopoulous – Int J Cancer 2018
EML4-ALK
variant V3 is a high-risk feature for ALK
+
NSCLC
V1/2
V3
N=67
V1 39%
V2 10%
V3 51%
V1
V3
V2
1. Gridelli, et al. Cancer Treat Rev 2014
2. D‘Arcangelo, et al. Curr Opin Oncol 2013
3. Hallberg, et al. Nat Rev Cancer 2013; Ou, et al. Oncologist 2012